natgillin/translations-raw huggingface dataset:
A method for preparing a compound for formula I, comprising contacting a compound of formula VI, with an acid under conditions suitable for forming an acid solvate of a compound of formula II: contacting the acid solvate of the compound of formula II with an amide under conditions suitable for forming an amide solvate of the compound of formula II; and contacting the amide solvate of the compound of formula II with an aqueous base comprising sodium ions under conditions suitable for forming the compound of formula I. The process of Claim 9, wherein: 
Postupak za pripremanje spoja s formulom I, [image] naznačen time da obuhvaća kontaktiranje spoja s formulom VI, [image] s kiselinom pod uvjetima pogodnim za tvorbu kiselog solvata spoja s formulom II: [image] kontaktiranje kiselog solvata spoja s formulom II s amidom u pod uvjetima pogodnim za tvorbu amidnog solvata spoja s formulom II; i kontaktiranje amidnog solvata spoja s formulom II s vodenom bazom koja sadrži natrijeve ione pod uvjetima pogodnim za tvorbu spoja s formulom I.
each independently represents an unsubstituted or substituted C1-8 alkyl group, an unsubstituted or substituted C2-8 alkenyl group, an unsubstituted or substituted C2-8 alkynyl group, an unsubstituted or substituted C3-8 cycloalkyl group, an unsubstituted or substituted C4-8 cycloalkenyl group, an unsubstituted or substituted C6-10 aryl group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted C1-8 acyl group, an unsubstituted or substituted (1-imino)C1-8 alkyl group, an unsubstituted or substituted carboxyl group, an unsubstituted or substituted carbamoyl group, an unsubstituted or substituted hydroxyl group, an unsubstituted or substituted amino group, an unsubstituted or substituted mercapto group, a substituted sulfonyl group, a halogeno group, a cyano group, or a nitro group; 
svaki neovisno predstavlja nesupstituiranu ili supstituiranu skupinu C1-8 alkil, nesupstituiranu ili supstituiranu skupinu C2-8 alkenil, nesupstituiranu ili supstituiranu skupinu C2-8 alkinil, nesupstituiranu ili supstituiranu skupinu C3-8 cikloalkil, nesupstituiranu ili supstituiranu skupinu C4-8 cikloalkenil, nesupstituiranu ili supstituiranu skupinu C6-10 aril, nesupstituiranu ili supstituiranu heterocikličku skupinu, nesupstituiranu ili supstituiranu skupinu C1-8 acil, nesupstituiranu ili supstituiranu skupinu (1-imino)C1-8 alkil, nesupstituiranu ili supstituiranu karboksilnu skupinu, nesupstituiranu ili supstituiranu karbamoil skupinu, nesupstituiranu ili supstituiranu hidroksilnu skupinu, nesupstituiranu ili supstituiranu amino skupinu, nesupstituiranu ili supstituiranu merkapto skupinu, supstituiranu sulfonil skupinu, halogenu skupinu, cijano skupinu, ili nitro skupinu;
The method according to any of the preceding embodiments, wherein the sample contains RNA and not more than four of: plasmid DNA, deoxy-oligonucleotides, deoxynucleoside monophosphates, ribonucleoside triphosphates and protein; and optionally wherein the sample does not contain genomic DNA and/or a cell membrane or fragments thereof. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uzorak sadrži RNA i najviše četiri od: plazmidne DNA, deoksioligonukleotida, deoksinukleozid-monofosfata, ribonukleozid-trifosfata i proteina; gdje uzorak ne mora sadržavati genomsku DNA i/ili staničnu membranu ili njezine fragmente.
a monoclonal antibody that is an antigen-binding fragment of the CHIR-12.12 monoclonal antibody or an antigen-binding fragment of a monoclonal antibody of any one of preceding items a)-f), where the fragment retains the capability of specifically binding to said human CD40 antigen. 
Monoklonalno antitijelo prema bilo kojem prethodnom zahtjevu, naznačeno time da je monoklonalno antitijelo antigen-vezujući fragment monoklonalnog antitijela, gdje navedeni fragment zadržava sposobnost specifičnog vezivanja za navedeni humani CD40 antigen.
a second configuration, wherein said loading elements are at a distance from the second central axis corresponding to a second radius which is greater than said first radius, so as to stretch the fabric strip and let it adhere to the loading elements themselves, for a length corresponding to the axial size of the loading elements, and so that the length of fabric strip protruding above from the loading elements gets back to the second central axis and is stretched as far as the first welt; and 
- druge konfiguracije, gdje su navedeni elementi za punjenje udaljeni od druge središnje osi koja odgovara drugom polumjeru, većem od navedenog prvog polumjera, radi rastezanja trake od tkanine i puštanja da prianja na same elemente za punjenje, u duljini koja odgovara aksijalnoj veličini elemenata za punjenje, te tako da se duljina trake od tkanine koja proviruje odozgo od elemenata za punjenje vrati do druge središnje osi i rastegne sve do prvog obruba; i
Z is selected from the group consisting of (CH2)m wherein m = 0, 1 or 2; 
Z jest odabran iz skupine koju čine (CH2)m gdje m = 0, 1 ili 2;
The mixtures of a compound according to the present invention and a pharmaceutically acceptable excipient may be compressed into solid dosage units, such as tablets, or be processed into capsules or suppositories. 
Smjese spoja prema ovom izumu s farmaceutski prihvatljivom pomoćnom tvari može se komprimirati u čvrste jedinice doziranja, poput tableta, ili oblikovati u kapsule ili supozitorije.
The pharmaceutical composition of unit dose according to claim 1, in which the topical corticoid is selected from the group of the following molecules: mometasone furoate, budesonide, beclomethasone, fluticasone furoate, fluticasone propionate and triamcinolone. 
Farmaceutski sprej pripravak prema jednom od prethodnih zahtjeva, u kojem se topikalni kortikoid odabire iz skupine koju čine sljedeće molekule: mometazon furoat, budezonid, beklometazon, flutikazon furoat, flutikazon propionat, triamcinolon.
More particularly, the anti-ligand of the present invention that is used to obtain the antibodies is the anti-ligand consisting of SEQ ID No. 20 or of SEQ ID No. 32 or any sequence having at least 75% sequence identity to the sequences set forth in SEQ ID No. 20 or SEQ ID No. 32 or any sequence 100% complementary thereof. 
- varijabilnu regiju teškog lanca (VH) koja ima sekvence amino kiseline navedene u SEQ ID No. 8; naznačen time da se navedeni ligand veže na anti-ligand koji se nalazi u sekvenci amino kiseline definiranoj sa SEQ ID No.20 ili SEQ ID No. 32, pri čemu je navedeni ligand odabran iz skupine koja se sastoji od protutijela, scFv fragmenta i Fab fragmenta.
A method for inhibiting VR1 function in a cell comprising contacting a cell, capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 or claim 20. 
Postupak za inhibiranje VR1 funkcije u stanici in vitro naznačen time da sadrži kontaktiranje stanice, koja može izražavati VR1, sa učinkovitom količinom spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20.
Preferred compounds of the present invention exhibit serotonin reuptake inhibition below 200 nM (IC50) in the assay above. 
Preferirani spojevi prema ovom izumu u očituju inhibiciju ponovne pohrane serotonina ispod 200 nM (ICso).
FIELD OF THE INVENTION The invention is related, in general, with the use of 5′-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs in the prevention and/or treatment of autoimmune diseases, as well as in the prevention and/or treatment of transplant rejections and, in particular, in the prevention and/or treatment of Multiple Sclerosis (MS). 
Uporaba 5'-metiltioadenozina (MTA), njegovih farmaceutski prihvatljivih soli i/ili prolijekova, gdje su navedeni prolijekovi esteri ili amidi MTA koji, nakon što su primijenjeni na osobi, daju MTA, direktno ili indirektno, navedenoj osobi, za pripravu medikamenta za (i) prevenciju i/ili liječenje autoimune bolesti ili za (ii) prevenciju i/ili liječenje odbacivanja transplantata.
wherein the meanings of n, Y, A and R1, R2 and R6 are as defined above, with a compound of formula (III) 
gdje su značenja n, Y, A teR', Ri R* kao što su definirana u patentnom zahtjevu 1, sa spojem formule (III)
The use according to claim 1 or 2, wherein B1 and B2 may be substituted with R2, OR2, SR2, or N(R2)2 and said B1 and B2 or said substituted B1 and B2 are independently selected from the group of: 
Uporaba prema zahtjevu 1 ili 2, naznačena time da B; i B, mogu biti supstituirani sa R,, OR,, SR, ili N(R2), 1 navedeni B, i B> ili navedeni supstituirani B; i B, su nezavisno odabrani iz skupine:
Rc and Rd together form a 3-7 member cyclic moiety, wherein the cyclic moiety is unsubstituted or substituted by at least one functional group suitable for conjugation of a polymeric moiety, and wherein R1 and R2 are the same or a different residue and are each independently selected from the group consisting of: 
(b) R"iR" zajedno formiraju 3-7 -članu cikličnu grupu, pri čemu je ciklična grupa nesupstituirana ili supstituirana sa najmanje jednom funkcionalnom grupom pogodnom za konjugaciju polimerne grupe, 1 pri čemu su R' i Rž isti ili različiti ostatak i svaki je nezavisno izabran iz grupe koju čine:
is selected from the series consisting of phenyl and Het2, wherein Het2 is selected from the series consisting of pyridinyl, pyrimidinyl, pyrazinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl and thiophenyl, which are bonded via a ring carbon atom, and wherein phenyl and Het2 are unsubstituted or substituted by one or two identical or different substituents selected from the series consisting of fluorine, chlorine, cyano, methyl, trifluoromethyl and methoxy; or 
je odabran iz niza koji čine fenil i Het2, pri čemu je Het2 odabran iz niza koji čine piridinil, pirimidinil, pirazinil, oksazolil, izoksazolil, tiazolil, izotiazolil i tiofenil, koji su vezani preko ugljikovog atoma u prstenu, i pri čemu su fenil i Het2 nesupstituirani ili supstituirani s jednim ili dva jednaka ili različita supstituenta odabrana iz niza koji čine fluor, klor, cijano, metil, trifluorometil i metoksi; ili
The transmitter preferably includes, on the outside of its housing, a representation or other diagram of a boat, as illustrated in Figure 1. 
Odašiljač poželjno uključuje na vanjskoj strani kućišta, prikaz ili neku drugu skicu plovila, kao što je prikazano na Slici 1.
The method according to claim 8, wherein said coating layer comprising said pigment flakes is applied by a method selected from the group consisting of screen printing, gravure/flexographic printing, and roller coating. 
Metoda u skladu s patentnim zahtjevom 13, naznačena time, da se navedeni premazni sloj koji sadrži navedeni ljuskasti pigment (3) nanosi metodom odabranim iz skupine koja se sastoji od sitotiska, graviranja/fleksografskog tiskanja i premazivanja valjkom. t>&
In further embodiments, a2-adrenergic receptor agonist is preferably brimonidine. Non-selective a1/a2 adrenergic receptor agonist may be selected from epinephrine, norepinephrine, isoproterenol, dipivefrin, pseudoephedrine, and mephentermine. 
Agonist za uporabu u skladu sa zahtjevom 3, naznačen time što je ne-selektivni agonist alfa 1/alfa 2 adrenergijskog receptora odabran od epinefrina, norepinefrina, izoproterenola, dipivefrina, pseudoefedrina, mefentermina i njihovih kombinacija.
X means -CH2- group, -NH- group, -NR10- group, or sulphur atom, or oxygen atom, or -SO- or -SO2 group - where R10 stands for straight or branched C1-4 alkyl group or C3-6 cycloalkyl group-; n is a value of zero, 1 or 2; - 
X označuje -CH2- skupinu, -NH- skupinu, -NR10- skupinu ili atom sumpora ili atom kisika ili -SO- ili -SO2- skupinu, gdje R10 predstavlja nerazgranatu ili razgranatu C1-4 alkilnu skupinu ili C3-6 cikloalkilnu skupinu; n ima vrijednost nula, 1 ili 2;
Suitable lubricants and antiadherents include, but are not limited to, stearates (magnesium, calcium and sodium), stearic acid, talc waxes, stearowet, boric acid, sodium chloride, DL-leucine, carbowax 4000, carbowax 6000, sodium oleate, sodium benzoate, sodium acetate, sodium lauryl sulfate, magnesium lauryl sulfate and the like. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što su lubrikant i antiadheziv izabrani iz grupe koju čine stearati kao što su magnezij stearat, kalcij stearat i natrij stearat; stearinska kiselina; talk voskovi; stearovet; borna kiselina; natrij klorid; DL-leucin; carbovax 4000; carbovax 6000; natrij oleat; natrij benzoat; natrij acetat; natrij lauril sulfat; i magnezij lauril sulfat.
Use of a drug delivery device comprising a fibrillar collagen matrix; and at least one drug substance, the at least one drug substance being substantially homogeneously dispersed in the collagen matrix, and the at least one drug substance being present in an amount sufficient to provide a duration of local analgesia, local anesthesia or nerve blockade which lasts for at least one day after administration for the manufacture of a medicament for providing local analgesia, local anesthesia or nerve blockade in the human or animal in need thereof, the analgesia, anesthesia or nerve blockade comprising administering the medicament at the site in a human or animal in need thereof wherein the drug delivery device comprises a plurality of collagen sponges, each collagen sponge having 3.6 to 8mg/cm3 type I collagen, and 2.0 to 6.0mg/cm3 bupivacaine hydrochloride. 
Uporaba naprave za dopremu lijeka koja sadrži matricu od fibrilarnog kolagena; i barem jednu ljekovitu tvar, najmanje jedna ljekovita tvar je sadržajno homogeno raspršena u matrici kolagena, za proizvodnju lijeka za omogućavanje lokalne analgezije, lokalne anestezije ili blokade živca kod potrebitog čovjeka ili životinje, analgezija, anestezija ili blokada živca obuhvaća davanje lijeka na određeno mjesto kod potrebitog čovjeka ili životinje pri čemu naprava za primjenu lijeka sadrži jednu ili nekoliko liofiliziranih kolagen spužvi koje ukupno sadrže 250 mg ili 200 mg anhidridnog bupivakain hidroklorida.
The method according to any one of the preceding claims, characterized in that the mineral impurities are selected from the group comprising varying amounts of dolomite and silica containing rocks or minerals, such as silica in the form of flint or quartz, feldspars, amphibolites, mica schists and pegmatite, as disseminations, nodules, layers within the calcium carbonate rock, or as side rocks. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da su mineralne nečistoće odabrane iz skupine koja sadrži različite količine stijena ili minerala koji sadrže dolomit i silicij, kao silicij u obliku kremena ili kvarca, fcldspata, amfibola, liskun škriljavca i pcgmatita, kao rasijani, nodularni, slojevi unutar stijenc od kalcijevog karbonata ili kao sporedne stijene.
The binding composition according to claim 7, wherein said acrylic component is selected between: a thermosetting aqueous acrylic resin and a polycarboxylic acid in a mixture with a polyol. 
Vezivna kompozicija prema patentnom zahtjevu 8, naznačena time što je navedena akrilna komponenta odabrana između: termoreaktivne vodene akrilne smole i polikarboksilne kiseline u smjesi s poliolom.
The process according to any one of the preceding aspects, wherein the polymer is selected from the group consisting of cellulose, cellulose acetate, polysulfones, polyamides, polyacrylic acid, polymethacrylic acid, polyacrylonitrile, polystyrene, polyethylene oxide, and mixtures thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, što je polimer odabran iz grupe koja se sastoji od celuloze, celuloznog acetata, polisulfona, poliamida, poliakrilne kiseline, polimetakrilne kiseline, poliakrilonitrila, polistirena, polietilen oksida i njihovih smjesa.
Process according to claim 14, wherein the C-terminal amino acid of the linear peptide obtained in point a) is lysine. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što je C-terminalna aminokiselina u dobivenom nerazgranatom peptidu u koraku a) lizin.
The floor underlayment of claim 13, wherein the pad layer comprises foil, cork, rubber, plastic, concrete, wood, organic material, inorganic material, composite material, a compound, or a combination thereof. 
Podni sklop u skladu s patentnim zahtjevom 7, naznačen time što je navedeni pokrovni sloj (11) najmanje jedno od folije, pluta, gume, plastike, betona, drva, organskih materijala, anorganskih materijala, kompozita, te smjesa.
The method of embodiment E39, wherein a population of rAAV particles with empty capsids, partially denatured capsids, less infectious capsid material, and/or partially full capsids are bound to the HIC medium after the elution with the medium salt buffer. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time što je populacija čestica rAAV s praznim kapsidima, djelomično denaturiranim kapsidima, manje zaraznim kapsidnim materijalom, i/ili djelomično punim kapsidima vezana na HIC medij nakon eluiranja s puferom srednje koncentracije soli.
After it has been introduced in a suitable way, the physiological saline is expelled from the space 15. 
Nakon što je ova čahura uvedena na odgovarajući način, fiziološka otopina se istisne iz prostora 15.
The mat of claim 1, wherein the protrusions of the plurality of protrusions have a height that tapers from a first height at a first edge of the base to a second height at a second edge of the base, the first height being greater than the second height. 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da više izbočina (201) visinom (D1, D2) variraju od prvog ruba osnove (320) do drugog ruba osnove (320).
adding water and an aqueous solution of a base to the reaction mixture from c), followed by heating; 
se dodaje voda i vodena otopina baze, nakon čega slijedi zagrijavanje, zatim
A pharmaceutical composition for use according to claim 2, wherein the oncological disease is selected from the group consisting of solid tumours. 
Uporaba u skladu sa zahtjevom 11, naznačena time, da onkološko oboljenje je izabrano iz skupine koju čine čvrsti tumori.
wherein at the location where the fibre elements are provided on the base film, a domain of a material mixture comprising the base film material and the fibre material is present between a domain of pure base film material and a domain of pure fibre material, and wherein the average thickness of the base film is less than the average thickness of the protrusion. A thermoplastic film intermediate comprising: an extruded base film comprising a stretchable polyolefin material comprising one or more layers; and 
pri čemu na mjestu gdje su vlaknasti elementi pruženi na baznoj foliji, prisutna je dominacija mješavine materijala koja obuhvaća osnovni materijal folije i vlaknasti materijal između dominacije čistog baznog materijala folije i dominacije vlaknastog materijala, tako da barem dio svakog vlaknastog elementa formira interfacijalnu mješavinu s baznom folijom i pri čemu je prosječna debljina bazne folije manja od prosječne debljine ispupčenja; pri čemu vlakna pokrivaju manje od 51% površine folije.
The present invention provides 2-(1H-indolylsulfanyl)-benzyl amine derivatives, formula I, which are serotonin reuptake inhibitors. 
Ovaj izum daje na raspolaganje 2-(1H-indolilsulfanil)-benzil aminske derivate formule I koji su inhibitori re-apsorpcije serotonina.
X ix S; R3, R4, R5, R6 K, L M, N and m are defined as in claim 1; comprising the step of treating a malonic diester with a suitable base in a suitable solvent, adding an unsubstituted or a substituted 2-chloro-3-nitropyridine, 3-chloro-4-nitropyridine or 4-chloro-3-nitropyridine, heating the reaction mixture until the reaction is complete, treating the reaction mixture with a mineral acid, and heating the reaction mixture until decarboxylation is complete to provide an unsubstituted or a substituted 2-methyl-3-nitropyridine, 3-methyl-4-nitropyridine or 4-methyl-3-nitropyridine. 
Ra, Ra, R5, Rs K, LM, Ni m su definirani kao u patentnom zahtjevu 1; koji se sastoji u koraku obrade diestera malonske kiseline pogodnom bazom u pogodnom otapalu, dodavanja nesupstituiranog ili supstituiranog 2-klor-3-nitropiridin, 3-klor-4-nitropiridina ili 4-klor-3-nitropiridina, grijanja reakcijske smjese dok reakcija ne bude gotova, obrade reakcijske smjese mineralnom kiselinom, te grijanja reakcijske smjese dok dekaboksilacija ne bude gotova, kako bi se dobilo nesupstituirani ili supstituirani 2-metil-3- nitropiridin, 3-metil-4-nitropiridin ili 4-metil-3-nitropiridin,
The composition for use according to claim 13 wherein said PI3K related disease or disorder is a cell proliferative disorder, preferably wherein the cell proliferative disorder is a cancer, such as papilloma, blastoglioma, Kaposi's sarcoma, melanoma, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, astrocytoma, head cancer, neck cancer, bladder cancer, breast cancer, lung cancer, colorectal cancer, thyroid cancer, pancreatic cancer, gastric cancer, hepatocellular carcinoma, leukemia, lymphoma, Hodgkin's disease and Burkitt's disease. 
Pripravak za uporabu prema zahtjevu 13 naznačen time da navedena bolest ili poremećaj povezan s PI3K je poremećaj proliferacije stanice, poželjno gdje je poremećaj proliferacije stanice rak, kao što je papilom, blastogliom, Kapozijev sarkom, melanom, karcinom ne-malih stanica pluća, rak jajnika, rak prostate, karcinom skvamoznih stanica, astrocitom, rak glave, rak vrata, rak mokraćnog mjehura, rak dojke, rak pluća, kolorektalni rak, rak tiroidne žlijezde, rak gušterače, rak želuca, hepatocelularni karcinom, leukemija, limfom, Hodgkinova bolest i
A lock and key system as defined in claim 5, wherein the longitudinal code pattern comprises two separate portions (110, 111, 112'; 183, 184) extending longitudinally in parallel and adjacent to each other on said longitudinal edge portion of said key blade (102; 182). 
Sustav ključa 1 brave kako je definirano u zahtjevu 5, naznačen time da uzdužni kodni uzorak sadrži dva odvojena dijela (110, 111, 112'; 183, 184) koji se pružaju uzdužno paralelno i međusobno susjedno na navedenom uzdužnom rubnom dijelu navedenog kraka ključa (102; 182).
A demountable pole dancing stage as claimed in Claim 1, wherein each of the support members comprises a generally rectangular frame having an inner upright member and an outer upright member and a pair of horizontal connecting members, and wherein, when in use, the lower connecting member bears on the ground. 
Sklopiva pozornica za ples na šipki iz zahtjeva 1, pri čemu se svaki nosivi element sastoji od pravokutnog okvira s unutarnjom uspravnom komponentom i vanjskom uspravnom komponentom te od dvije vodoravne spojne komponente, pri čemu se, kad je pozornica u uporabi, donja spojna komponenta naslanja na tlo (podlogu).
• said sweetener composition comprises high intensity sweetener in an amount sufficient to provide to the sugar replacement composition a sweetness about equal to the sweetness of sugar, 
- > sladilo velike slatkoće u količini dovoljnoj da slatkoća sastavine koja zamjenjuje šećer bude približno jednaka slatkoći šećera, gdje rečeni oligosaharid sadržava -
The compound or pharmaceutically acceptable salt of claim 13, wherein R5 is methyl. 
Spoj ili farmaceutski prihvatljiva sol sukladno patentnom zahtjevu 1, izabrano od:
wherein the amount of non-conjugated antibody is in the range of 10-40% by weight comprising: 
O gdje je količina nekonjugiranog protutijela u rasponu od 10-40%, težinski, naznačen time što se sastoji u: a.
The use of one of claims 12 or 13, wherein rifaximin t is identified in the mixture by detecting peaks from the X-ray powder diffraction pattern of the single crystal of rifaximin t in the X-ray powder diffraction pattern of the mixture. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 12 ili 13, naznačena time što se rifaksimin t identificira u smjesi detektiranjem maksimuma iz uzorka difrakcije rendgenskih zraka na prahu za monokristal rifaksimina t u uzorku difrakcije rendgenskih zraka na prahu za smjesu.